Vraylar is the brand name for cariprazine, an atypical antipsychotic manufactured by AbbVie. The FDA first approved cariprazine on September 17, 2015 (NDA 204370) for schizophrenia and acute manic or mixed episodes of bipolar I disorder in adults. Subsequent FDA approvals expanded the label to cover depressive episodes associated with bipolar I disorder and, in December 2022, adjunctive treatment of major depressive disorder (MDD) in adults. Vraylar is also approved for schizophrenia in adolescents aged 13 and older and for bipolar I mania in patients 10 and older. Cariprazine works through partial agonist activity at dopamine D3 and D2 receptors and serotonin 5-HT1A receptors, and antagonist activity at 5-HT2A receptors, a mechanism that differentiates it from older antipsychotics.
Vraylar's 2026 wholesale list price is approximately $1,595 per 30-day supply. What you actually pay depends on your insurance type, whether your plan places Vraylar on a higher formulary tier, and whether you qualify for AbbVie's savings programs. Because antipsychotics are a protected class under Medicare Part D rules, virtually all Part D plans must cover Vraylar, though prior authorization may still be required. Patients with commercial insurance can access the VRAYPAY savings card, which caps monthly cost at $0 for many eligible patients. Uninsured and underinsured patients can apply for the myAbbVie Assist patient assistance program, which offers free Vraylar for households with income at or below 600% of the federal poverty level. You can also compare current cash prices across major pharmacy chains using GoodRx and similar tools, where prices typically range from $1,445 to $1,620 with discount coupons.
The Inflation Reduction Act of 2022 (Public Law 117-169) selected cariprazine (Vraylar) for the second round of Medicare drug price negotiations. CMS completed negotiations with AbbVie in 2025 and announced a Maximum Fair Price of $770 per 30-day supply, down from a 2024 list price of approximately $1,376, a reduction of about 44 percent. That negotiated price takes effect January 1, 2027. For Medicare patients facing Vraylar costs in 2026, the annual $2,100 Part D out-of-pocket cap under the IRA provides the main protection while waiting for the 2027 Maximum Fair Price. Patients who cannot afford 2026 costs should check whether they qualify for Medicare's Low Income Subsidy (Extra Help) at medicare.gov or for the myAbbVie Assist program. The 2026 Part D out-of-pocket cap of $2,100 replaced the old catastrophic phase structure as part of the same Inflation Reduction Act.
What Vraylar Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same vraylar can cost many times more at a hospital than at your local pharmacy:
2026 Vraylar Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $1,450 - $1,800/month | List price without insurance for a 30-day supply of capsules in 2026. GoodRx and SingleCare coupons reduce this to $1,445 - $1,620 at major chains. |
| Medicare Part D (2026) | $0 - $400/month, capped at $2,100/year total | Antipsychotics are a Medicare protected class, so virtually all plans cover Vraylar. Prior authorization may apply. Annual OOP cap of $2,100 in 2026 under the Inflation Reduction Act. |
| Commercial insurance | $0 - $300/month after prior authorization | Prior authorization is standard. VRAYPAY savings card can reduce cost to $0/month for eligible commercially insured patients (up to $10,000/year). |
| VRAYPAY manufacturer savings card | $0/month for eligible commercially insured patients | Annual maximum benefit of $10,000 per calendar year. Not available to Medicare, Medicaid, TRICARE, or VA patients. Contact 1-844-4VRAYLAR. |
| Medicaid | $1 - $4/prescription, with prior authorization | Antipsychotics are typically covered by Medicaid as an essential drug class. State copay rules apply; most patients pay $4 or less. |
Retail prices reflect 2026 GoodRx and pharmacy survey data. Part D ranges depend on your plan's formulary tier and where you are in the benefit year. IRA Round 2 Maximum Fair Price of $770 takes effect 2027-01-01.
Source: CMS Part D 2026 benefit design, AbbVie VRAYPAY and myAbbVie Assist programs, GoodRx, CMS IRA Round 2 negotiated prices
Why Hospitals Charge So Much
Vraylar is an outpatient oral capsule taken once daily at home, so inpatient hospital billing for Vraylar is uncommon. When it does appear on a hospital itemized bill, usually because a patient is admitted to a psychiatric facility or general hospital while on a chronic Vraylar prescription, the facility will charge a markup on top of its drug acquisition cost. Hospital pharmacy acquisition costs for specialty brand drugs like Vraylar already reflect the $1,595 wholesale list price; on top of that, facility fees, pharmacy handling fees, and nursing documentation charges inflate the line-item substantially. Inpatient psychiatric facilities and general hospitals routinely bill oral antipsychotics at two to four times the retail pharmacy rate, meaning a 30-day-equivalent supply of Vraylar may appear on a bill at $2,800 to $5,500 or more in a hospital setting in 2026.
Three factors drive hospital markups for Vraylar specifically. First, psychiatric admissions often require extended inpatient stays measured in weeks, so the per-admission exposure to daily Vraylar charges adds up quickly. Second, hospitals frequently substitute equivalent antipsychotics based on their formulary, and if a patient insists on brand Vraylar (for example, to maintain a stable regimen), the facility may classify it as a non-formulary drug and charge the highest available rate. Third, because Vraylar is a relatively new brand without a generic, the hospital cannot substitute a cheaper alternative the way it might with an older antipsychotic like haloperidol or aripiprazole. If you receive an inpatient bill showing Vraylar at more than $2,000 for a partial supply, request an itemized bill, verify the National Drug Code (NDC), and compare the charge to the 2026 wholesale acquisition cost of approximately $1,595 per 30-day supply.
Patient Assistance Programs
AbbVie, the manufacturer of Vraylar, offers two primary financial assistance options. The VRAYPAY savings card targets commercially insured patients and can reduce the monthly cost to $0. The myAbbVie Assist patient assistance program (PAP) provides free Vraylar to uninsured and underinsured patients who meet income requirements. Together, these programs cover the two most common affordability scenarios: patients with private insurance who still face high cost-sharing, and patients with no or limited insurance who pay the full cash retail price. Medicaid covers Vraylar for qualifying patients at a copay of $4 or less in most states, as antipsychotics are classified as an essential drug category.
Patient assistance programs for Vraylar| Manufacturer program | Cost / Benefit | How to apply |
|---|
| VRAYPAY Savings Card (AbbVie) | $0/month for eligible commercially insured patients; annual maximum benefit of $10,000 per calendar year | vraylar.com/savings-sign-up |
| myAbbVie Assist Patient Assistance Program | Free Vraylar for uninsured or underinsured patients with household income at or below 600% of the federal poverty level | abbvie.com/patients/patient-support/patient-assistance.html |
| Medicare Low Income Subsidy (Extra Help) | Vraylar copay as low as $12.65/month for qualifying Medicare beneficiaries with limited income | ssa.gov/medicare/part-d/extra-help |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies; typically $1,445 to $1,560 with discount at major chains | needymeds.org |
Manufacturer savings cards (VRAYPAY) are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries under federal anti-kickback statute (42 U.S.C. 1320a-7b). If you have government insurance, apply for the myAbbVie Assist patient assistance program or Medicare's Extra Help (Low Income Subsidy) instead. For Medicare patients with income below 150% FPL, myAbbVie Assist requires proof that you have applied for or been denied Medicare Extra Help before the application can be evaluated.
Source: AbbVie VRAYPAY savings program, AbbVie myAbbVie Assist patient assistance program, Medicare Extra Help (SSA), NeedyMeds.org
Medicare Part D
Vraylar is a Medicare Part D drug. Antipsychotics, including cariprazine, are classified as a protected drug class under the Medicare Modernization Act of 2003, which means Medicare Part D plans must cover all or nearly all drugs in the class regardless of formulary tier preferences. In practice, this means virtually every Part D plan covers Vraylar, giving Medicare beneficiaries with schizophrenia, bipolar I disorder, or bipolar depression access to the medication. However, plans may still require prior authorization to confirm the diagnosis and appropriateness of Vraylar over lower-cost antipsychotics. For 2026, your total out-of-pocket spending on all Part D drugs combined is capped at $2,100 under the Inflation Reduction Act, replacing the former catastrophic-phase coinsurance structure. Once you reach $2,100 in annual Part D out-of-pocket costs, you pay $0 for the rest of the year.
Medicare beneficiaries with limited income can significantly reduce their Vraylar costs through the Medicare Low Income Subsidy, also called Extra Help. Qualifying beneficiaries pay a Vraylar copay of $12.65 or less per 30-day supply in 2026, compared to hundreds of dollars without the subsidy. Extra Help is available to Part D enrollees with income up to 150% of the federal poverty level and limited assets. You can apply for Extra Help through the Social Security Administration at ssa.gov or through your State Health Insurance Assistance Program (SHIP). The Medicare Prescription Payment Plan, available since 2025, also lets you spread your annual Part D out-of-pocket costs evenly across monthly payments rather than paying a large amount in a single month when you first fill Vraylar at the start of the year.
Starting January 1, 2027, the IRA Round 2 Maximum Fair Price of $770 per 30-day supply will apply to Vraylar for Medicare beneficiaries, down from the 2026 list price of approximately $1,595. That 52-percent reduction represents the largest direct cost relief Vraylar Medicare patients will see under the Inflation Reduction Act's negotiation program. Until the 2027 price takes effect, Medicare patients in 2026 should prioritize the $2,100 annual OOP cap, the Extra Help subsidy if income-eligible, and the Medicare Prescription Payment Plan to manage monthly cash flow.
Common Vraylar Billing Errors
If you received a Vraylar bill above $300 with commercial insurance, or above $500 per month with Medicare Part D before hitting the $2,100 cap, check for these billing issues before paying:
- Prior authorization not submitted or lapsed: most commercial plans and some Medicare plans require prior authorization for Vraylar. If your prescriber's office did not submit a PA or it expired, you may be paying cash unnecessarily.
- VRAYPAY manufacturer coupon not applied: if you are commercially insured and the pharmacist did not run the VRAYPAY manufacturer coupon card, your cost could be hundreds of dollars per month instead of $0. Ask the pharmacist to reprocess the claim with the VRAYPAY BIN/PCN number.
- Formulary tier error: if your Part D plan places Vraylar on Tier 4 (non-preferred brand) when a formulary exception could move it to Tier 3, your copay could drop significantly. Ask your prescriber to file a formulary tier exception request.
- Charged past the $2,100 Part D annual out-of-pocket cap: once you hit $2,100 in total annual Part D OOP spending in 2026, you should pay $0 for covered drugs for the rest of the year. If you are still being billed, contact your plan.
- Inpatient hospital charge for Vraylar at $3,000 or more when the retail pharmacy acquisition cost is approximately $1,595. Request an itemized bill and the NDC code; the hospital markup can often be negotiated or appealed.
- Wrong NDC billed: Vraylar comes in multiple capsule strengths (1.5 mg, 3 mg, 4.5 mg, 6 mg). If the pharmacy bills the wrong strength NDC, your plan may reject the claim or charge a different tier copay.
Frequently Asked Questions
How much does Vraylar cost without insurance in 2026?
Vraylar's retail cash price in 2026 ranges from approximately $1,450 to $1,800 per month for a 30-day supply of capsules, depending on the pharmacy and dosage strength. The wholesale list price is about $1,595 per 30-day supply. With a free GoodRx or SingleCare coupon, the cash price at Kroger runs around $1,445, at Walgreens about $1,542, at CVS about $1,559, and at Walmart about $1,579. There is no generic cariprazine available as of 2026, so these prices reflect the brand only. Uninsured patients with income at or below 600% of the federal poverty level may qualify for free Vraylar through the myAbbVie Assist patient assistance program.
Is there a generic for Vraylar in 2026?
No generic cariprazine is commercially available as of June 2026. Aurobindo Pharma received FDA final approval for generic cariprazine capsules on December 16, 2025, but has not launched the product commercially due to ongoing patent protection. Vraylar's patents protect the brand through approximately September 2029, so generic market entry is not expected before 2029 or 2030. For Medicare patients, the IRA Round 2 Maximum Fair Price of $770 per month, effective January 1, 2027, provides meaningful price relief ahead of generic entry. Older generic antipsychotics (aripiprazole, quetiapine, risperidone) cost $10 to $40 per month but are different molecules and are not direct substitutes.
Does Medicare Part D cover Vraylar?
Yes. Antipsychotics, including cariprazine (Vraylar), are a protected drug class under Medicare law, which means virtually all Part D plans must cover them. Your specific cost depends on your plan's formulary tier and where you are in the 2026 benefit year. The annual out-of-pocket cap for all Part D drugs combined is $2,100 in 2026 under the Inflation Reduction Act. Medicare beneficiaries with limited income should check eligibility for Extra Help (Low Income Subsidy), which reduces Vraylar's copay to $12.65 or less per month. Starting January 1, 2027, the IRA Round 2 Maximum Fair Price of $770 per 30-day supply applies for Medicare patients.
Can I use the Vraylar savings card (VRAYPAY) with Medicare?
No. Federal anti-kickback statute (42 U.S.C. 1320a-7b) prohibits manufacturer copay savings cards from being used by anyone covered by Medicare, Medicaid, TRICARE, or VA benefits. The VRAYPAY card is available only to commercially insured patients and provides up to $10,000 per calendar year in copay assistance. If you are on Medicare and cannot afford Vraylar, your options are: (1) apply for Medicare's Low Income Subsidy (Extra Help) at ssa.gov, which reduces your copay to $12.65 or less, (2) apply for the myAbbVie Assist patient assistance program at abbvie.com if your income is at or below 600% of the federal poverty level, or (3) ask your Part D plan to process a formulary tier exception request.
How do I apply for the myAbbVie Assist patient assistance program for Vraylar?
Start your application online at abbvie.com/patients/patient-support/patient-assistance.html or call 1-800-222-6885. You must be a US resident with household income at or below 600% of the federal poverty level and have limited or no prescription drug insurance. Gather: your most recent federal tax return (or 4 consecutive pay stubs), proof of US residency, a valid Vraylar prescription, and your insurance documentation. If you have Medicare Part D with income below 150% FPL, you must first apply for or be denied Extra Help through the Social Security Administration. Applications submitted by fax (1-866-250-2803) or online take 7 to 14 business days to process. If approved, AbbVie ships free Vraylar directly to your home or prescriber's office, with annual renewal required.
Does the IRA negotiated price apply to Vraylar in 2026?
Not yet in 2026. Vraylar (cariprazine) was selected for the IRA Round 2 Medicare drug price negotiation program. CMS negotiated a Maximum Fair Price of $770 per 30-day supply with AbbVie, representing a reduction of approximately 44 percent from the 2024 list price of $1,376. That Maximum Fair Price takes effect January 1, 2027, not 2026. For 2026, Medicare beneficiaries are protected by the Inflation Reduction Act's $2,100 annual Part D out-of-pocket cap, the Extra Help subsidy for low-income patients, and the Medicare Prescription Payment Plan for spreading costs across the year.
What if my insurance denies coverage for Vraylar?
Request a written denial notice with the specific reason. File a formal appeal within 60 days with your prescriber's letter of medical necessity. Ask your psychiatrist to request a peer-to-peer review with the plan's medical director, as antipsychotics are a protected class under Medicare and many commercial plans, limiting grounds for denial. If step therapy is required, ask for a step-therapy override documenting prior medication failures or clinical contraindications. If appeals fail, apply for the myAbbVie Assist patient assistance program (free Vraylar for 600% FPL or below). For commercial plan external appeals, contact your State Department of Insurance. For Medicare Part D external review, request escalation to an Independent Review Organization.
How does Vraylar compare to other antipsychotics in cost?
Vraylar is among the most expensive antipsychotics available in 2026, reflecting its brand-only status. For comparison: aripiprazole (generic Abilify) costs $10 to $40 per month, quetiapine (generic Seroquel) costs $15 to $50 per month, and risperidone (generic Risperdal) costs $10 to $30 per month. Other brand antipsychotics, such as Latuda (lurasidone) and Rexulti (brexpiprazole), carry similar $1,200 to $1,800 per month list prices. Vraylar's IRA Round 2 Maximum Fair Price of $770 per month for Medicare patients, effective 2027, will narrow the gap with some commercial pricing and bring it closer to formulary-preferred tier costs. Switching antipsychotics is a clinical decision, not a cost-only decision, and should be made with your prescribing psychiatrist.
